Last reviewed · How we verify
NCT06379880: FEGALA
Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution
NA trial testing CONTINUUM+ CONNECT remote monitoring in Prostatic Neoplasms in 411 participants. Completed in 26 January 2026.
7 November 2025
Quick facts
| Lead sponsor | Centre Paul Strauss |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 411 |
| Start date | 25 April 2024 |
| Primary completion | 7 November 2025 |
| Estimated completion | 26 January 2026 |
| Sites | 13 locations across France |
Drugs / interventions tested
- CONTINUUM+ CONNECT remote monitoring
Conditions studied
- Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
- Lung Neoplasms — all drugs for Lung Neoplasms →
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Colorectal Neoplasms — all drugs for Colorectal Neoplasms →
Sponsor
Centre Paul Strauss — full company profile →
Who can join
18 and older, any sex, with Prostatic Neoplasms or Lung Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
FEGALA is a comparative, multicenter, randomized, prospective, open-label study comparing the results observed at 3 months (± 15 days) on the EORTC QLQ-C30 scale in a group of patients with metastatic cancer followed on an outpatient basis and benefiting from the CONTINUUM+ CONNECT solution (with or without nursing support at home) versus comparable patients benefiting from conventional monitoring.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06379880
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostatic Neoplasms
Currently open trials in the same condition.
- NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
- NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
- NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
- NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
- NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting
Other Centre Paul Strauss trials
Trials by the same sponsor.
- NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
- NCT07204535 — Post-TRaUmatic STress Disorder Induced by Gynecological Brachytherapy · not yet recruiting
- NCT07069790 — Effects of Chemotherapy Treatment on Metaboreflex, Mechanoreflex, and Baroreflex Function: PROTECT-08B Study · NA · recruiting
- NCT05653622 — Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operate · Phase 2 · recruiting
- NCT06330142 — Hippotherapy Teenager-pediatric Radiotherapy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06379880 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Paul Strauss
- Last refreshed: 4 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06379880.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing